Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment

Nutrients. 2021 May 22;13(6):1770. doi: 10.3390/nu13061770.

Guillermo Bastida 1, Claudia Herrera-de Guise 2, Alicia Algaba 3, Yolanda Ber Nieto 4, Jose Manuel Soares 5, Virginia Robles 2, Fernando Bermejo 3, Esteban Sáez-González 1, Fernando Gomollón 6, Pilar Nos 1


Author information

  • 1Department of Gastroenterology, CIBEREHD, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain.
  • 2Crohn-Colitis Care Unit, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain.
  • 3Department of Gastroenterology, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Hospital Universitario de Fuenlabrada, 28046 Madrid, Spain.
  • 4Department of Gastroenterology, Hospital Universitario San Jorge, 22004 Huesca, Spain.
  • 5Department of Gastroenterology, Hospital Pedro Hispano, 4454-509 Matosinhos, Portugal.

6IBD Unit, Digestive Diseases Service, Instituto de Investigación Sanitaria de Aragón (IIS), CIBEREHD, Hospital Clínico Universitario "Lozano Blesa", 50009 Zaragoza,


Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p < 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients' QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%); they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients' QoL. In conclusion, SI should be considered in IDA-IBD patients.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.